BackAerovate Therapeutics Overview

Aerovate Therapeutics Research & Development

Research & Development expenses for AVTE.

Quarterly R&D Expenses

$36.05M

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$129.17M
↑ 290.17% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin